Who we are
The Eos Team bring a wide range of personal experience as business founders, scientists, record breakers, industry leaders, and government advisors.
Kevin Grainger
Eos Advisory Chairman
Andrew McNeill Phd
Eos Advisory Managing Partner
Mark Beaumont BEM
Eos Advisory Partner
Rick Clark
Eos Advisory Partner
Ana Stewart
Eos Advisory Partner
Chris Brinsmead CBE
Eos Advisory Partner
Calum Keddie
Investment Executive
Valerie Jolliffe
Investment Committee & Fund Manager
Ben Hasselgren
Information Technology & Design
What Eos invests in
Eos are specialists in deep science, engineering and technology, taking businesses from start-up and spinout stage, through to Series A and beyond. We back ventures that have global potential, protectable IP, a clear commercial strategy, and a management team that we can have a significant relationship with for what is typically a 5-8 year investment journey. Our approach is very selective and hands-on.
We only work with companies that are strongly motivated by the global challenges they are addressing, as well as their financial growth.
We focus on seed funding in the following four impact areas:
Disease Diagnosis,
Prevention & Treatment
- Disease Diagnosis, Prevention & Treatment
Energy Security Issues,
Climate Change & Pollution
- Energy Security Issues, Climate Change & Pollution
Food &
Water Security
-
Food & Water
Security
Improvement & Sustainability
of Industrial Processes
- Improvement & Sustainability of Industrial Processes
How Eos invests
We are seed stage investors in science, engineering and technology innovations which impact key global issues through an Angel Syndicate, an Innovation Fund and Venture Partnerships.
We also have Scottish Enterprise co-investment status. The breadth of this co-investment is important for scaling, balancing of risk and also to build relationships with people and organisations who can understand and help our businesses grow over the long term.
A growing & thriving portfolio
Eos works closely with its portfolio companies to give them not just investment, but also direction and introductions. This ‘smart money’ means that the value we bring is more than the financial backing, and we have the experience to know that companies don’t grow in a straight line, or always follow the planned hockey curve. The start-up and spin out journey are often a rollercoaster, so we are realistic about future capital requirements and contingencies. As we celebrate 6 years, we are starting to see our earliest investments mature according to our 5-8 year plan.
We have often had to help companies pivot their business plans to continue their growth and impact. All of our companies have grown through sales and follow on investments, which is a track record we are proud of. We have had our first exit event in March 2021 and out of the 13 invested companies 6 have had follow on rounds at either Series A and B.
0
Investee Businesses
£
0
m
Cumulative Investments
0
:1
Co-investment ratio
Lab-on-a-chip’ technology that delivers oil analysis 1000x faster and 10x cheaper than the current ‘send the sample to laboratory approach.
Europes first cancer drug accelerator. Finding assets, creating spin-outs, commercialising cancer therapies.
ABUNDA mycoprotein is a fermented food ingredient, rich in protein and fibre. Naturally fortified in B12, zinc and iron. ABUNDA is highly nutritious. The fibrous nature of the product gives an outstanding meaty texture, naturally.
Angel Syndicate
A Syndicate of like-minded entrepreneurs was how Eos started in 2014 and it has since grown to a private members group of around 60 individuals who typically meet 4 times a year either in St Andrews or online to consider investment opportunities that the Eos executive has pre-screened. Members are usually presented with 2-3 investment opportunities per meeting. These have been carefully selected from a large pool of applications, not only for the strength of the underlying science or technology, but also for their market potential, management team and exit potential. The investment opportunities are predominantly Scottish based businesses, often spin-outs from Universities and they will always be seed stage, generally pre-revenue.
Innovation Fund
The Eos EIS Innovation Fund backs businesses in the same impact areas as the Syndicate, so has the ability to co-invest or invest separately. The Fund is designed for investors and financial advisors who do not have the desire, the time or the ability to attend pitch meetings and make direct investment decisions as syndicate members. Funds are diversified into a portfolio of at least 5 businesses, and recommendations are made by the Investment Committee, made up of the Eos partners, with the final investment decision held by our Fund Manager.
The businesses that we back all aim to have a positive impact on the world around us, whilst also delivering a commercial return. By addressing global challenges, we are backing Scottish innovation that has a significant market opportunity, whilst acknowledging the risks of early stage investing. Eos alongside our network of advisors and investment directors work with innovators to build the foundational years of companies.
Venture Partners
Eos has extensive access to the Scottish start-up market and the ability to lead due diligence and transactions on deep science and technology. We look for Venture Partners who have a range of complimentary strengths, the ability to invest at Series A and trade connections and experience.
Each Venture Partnership is unique and based on the overlap of interests. We are seeing particular growth in life science and climate change opportunities, and are actively looking for new UK and international Venture Partnerships in these areas, whilst continuing to invest across our four impact areas.
Get in touch
General enquiries
Address
Eos Advisory LLP,
Kinburn Castle,
Doubledykes Road, St Andrews,
KY16 9DR
